Compare LVO & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LVO | CTSO |
|---|---|---|
| Founded | 2009 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.9M | 45.9M |
| IPO Year | N/A | N/A |
| Metric | LVO | CTSO |
|---|---|---|
| Price | $5.15 | $0.67 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $13.00 | $5.38 |
| AVG Volume (30 Days) | 100.5K | ★ 114.9K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $86,702,000.00 | $36,979,520.00 |
| Revenue This Year | N/A | $9.51 |
| Revenue Next Year | $28.01 | $24.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 23.89 |
| 52 Week Low | $3.92 | $0.60 |
| 52 Week High | $16.00 | $1.61 |
| Indicator | LVO | CTSO |
|---|---|---|
| Relative Strength Index (RSI) | 59.28 | 43.59 |
| Support Level | $4.99 | $0.66 |
| Resistance Level | $5.49 | $0.76 |
| Average True Range (ATR) | 0.35 | 0.07 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 73.02 | 24.33 |
LiveOne Inc, formerly LiveXLive Media Inc is a premium internet network devoted to live music and music-related video content. The company has been building an online destination for music fans to enjoy live performances from music venues and music festivals around the world, such as Rock in Rio, Outside Lands Music and Arts Festival, and Hangout Music Festival, as well as original content, artist exclusives, and industry interviews. The Company operates mainly through three segments, PodcastOne, Slacker, and Media Group, with a majority of its revenue derived from the Slacker segment.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.